free counter
Health And Medical

New approach to nasal vaccine delivery may lead to better vaccines for HIV and COVID-19

New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
A University of Minnesota assistant professor is section of a team which has developed a fresh solution to effectively deliver vaccines through the nose which could result in better protection against diseases like HIV and COVID-19. Credit: Hartwell Immunoengineering Lab, University of Minnesota

A University of Minnesota assistant professor is section of a team which has developed a fresh solution to effectively deliver vaccines through mucosal tissues in the nose which could result in better protection against pathogens like human immunodeficiency virus (HIV) and SARS-CoV-2, the herpes virus that triggers COVID-19.

The researchers tested the technology on mice and and discovered that the generated strong immune responses, paving just how for further study and development of nasal vaccines.

The analysis is published in Science Translational Medicine.

Historically, nasal vaccineswhich will be administered by way of a nebulizer or sprayhave been difficult to create successfully. The mucus in the typically clears out or reduces the vaccine’s components, such as for example , before they are able to access underlying tissues to activate your body’s immune cells.

However, nasal vaccines have the potential to create a lot more immunity than current vaccines administered by injection with needles. It is because for most diseases which are transmitted through top of the respiratory system, such as for example COVID-19, nasal vaccines have the potential to trigger immune responses in the precise regions of infectionthe nose, mouth, and lungs. Some nasal vaccines do exist, but most use live attenuated pathogens, which can’t be given to those who are immunocompromised.

“Traditional vaccines which are injected aren’t usually aimed toward establishing immunity in these mucosal tissues,” explained Brittany Hartwell, first author on the paper and an assistant professor in the University of Minnesota Twin Cities Department of Biomedical Engineering. “They’re more aimed toward establishing immunity in the bloodsort of such as a backup defense. However the notion of establishing immunity in the mucosal areas, just like the nose, is that it establishes more of a frontline defense that may better drive back transmission of the diseases.”

Hartwell said that with this particular new vaccine, not merely did they establish strong mucosal antibody responses, however they also activated really strong antibody responses in the blood.

“So, it’s similar to we’re establishing a frontline and backup defense simultaneously,” she said.

Hartwell and her team have discovered a method to help vaccine antigens bypass the mucosal barriers in the nose by engineering them to bind onto a protein called albumin, which naturally occurs in the and contains the opportunity to bypass these roadblocks. The antigens could then effectively “hitchhike” on albumin to access their destinationthe immune tissues underlying in the noseto start activating an immune response.

And, the researchers’ vaccine proved able to generating immunity not only in the nose, however in other mucosal tissues of your body as well, such as the upper the respiratory system, lungs, and genitourinary tract. The latter is particularly relevant for vaccinating against a virus like HIV, that is transmitted through the websites.

“That is really significant for the field of mucosal vaccination,” Hartwell said. “It shows something new, that we’ve designed a vaccine with the capacity of overcoming barriers to delivery which have historically plagued the development of other mucosal vaccines. It’s particularly relevant at this time because we are all surviving in the midst of the COVID pandemic that’s continuing to affect our lives. So when long as there’s spread and transmission, the herpes virus has a possiblity to evolve into new variants with the potential to be harmful. This research shows the development of a slightly different sort of vaccine which could provide better still protection than what we now have by blocking transmission, preventing us from catching and passing the herpes virus onto others.”

Hartwell is continuing to review and develop this new vaccine technology in her lab at the University of Minnesota Twin Cities and hopes to adapt it to other diseases and illnesses later on.



More info: Brittany L. Hartwell et al, Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to operate a vehicle mucosal and systemic immunity, Science Translational Medicine (2022). DOI: 10.1126/scitranslmed.abn1413

Citation: New approach to nasal vaccine delivery may lead to better vaccines for HIV and COVID-19 (2022, August 10) retrieved 10 August 2022 from https://medicalxpress.com/news/2022-08-method-nasal-vaccine-delivery-vaccines.html

This document is at the mercy of copyright. Aside from any fair dealing for the intended purpose of private study or research, no part could be reproduced minus the written permission. This content is provided for information purposes only.

Read More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker